Dyne Therapeutics (DYN) Amortization of Deferred Charges (2021 - 2026)
Dyne Therapeutics (DYN) recorded quarterly Amortization of Deferred Charges of -$271000.0 in Q1 2026, up 30.15% quarter-over-quarter from -$388000.0 in Q4 2025, and up 56.01% on a YoY basis from -$173710.7 in Q1 2025.
Dyne Therapeutics (DYN) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Dyne Therapeutics' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at -$271000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 56.01% year-over-year to -$271000.0; the TTM figure through Mar 2026 stood at -$1.5 million (up 59.7% YoY), while the FY2025 annual figure was -$1.8 million, up 49.08% from the prior year.
- Amortization of Deferred Charges was -$271000.0 for Q1 2026 at Dyne Therapeutics, up from -$388000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $605000.0 in Q1 2022 to a low of -$1.3 million in Q2 2024.
- Historically, Amortization of Deferred Charges has averaged -$325647.1 across 5 years, with a median of -$365000.0 in 2023.
- The sharpest annual moves came in 2023 and 2025: Amortization of Deferred Charges tumbled 792.86% in 2023, then surged 63.51% in 2025.
- A 5-year view of Amortization of Deferred Charges shows it stood at $28000.0 in 2022, then sank by 792.86% to -$194000.0 in 2023, then slumped by 330.93% to -$836000.0 in 2024, then soared by 53.59% to -$388000.0 in 2025, then surged by 30.15% to -$271000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at -$271000.0 (Q1 2026), -$388000.0 (Q4 2025), and -$368000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -271,000.00 |
| Mar 31, 2026 | -271,000.00 |
| Dec 31, 2025 | -388,000.00 |
| Dec 31, 2025 | -388,000.00 |
| Sep 30, 2025 | -368,000.00 |
| Sep 30, 2025 | -368,000.00 |
| Jun 30, 2025 | -463,000.00 |
| Jun 30, 2025 | -463,000.00 |
| Mar 31, 2025 | -616,000.00 |
| Mar 31, 2025 | -616,000.00 |
| Dec 31, 2024 | -836,000.00 |
| Dec 31, 2024 | -836,000.00 |
| Sep 30, 2024 | -976,000.00 |
| Sep 30, 2024 | -976,000.00 |
| Jun 30, 2024 | -1.27 Mn |
| Jun 30, 2024 | -1.27 Mn |
| Mar 31, 2024 | -523,000.00 |
| Mar 31, 2024 | -523,000.00 |
| Dec 31, 2023 | -194,000.00 |
| Dec 31, 2023 | -194,000.00 |